FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2022/10/046929 [Registered on: 31/10/2022] Trial Registered Prospectively
Last Modified On: 28/10/2022
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Follow Up Study 
Study Design  Other 
Public Title of Study   Difference in the distance walked in six minute walk test before and after radiation therapy in breast cancer patients 
Scientific Title of Study   Estimating the minimally clinical important difference of six minute walk distance in patients with breast cancer 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
Nil  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Gouri Elurker  
Designation  MPT  
Affiliation  Father Muller Medical College  
Address  Father Muller Medical College, Physiotherapy Department, Kankanady, Mangalore Dakshina Kannada Karnataka 575002 India

Dakshina Kannada
KARNATAKA
575002
India 
Phone  7447240180  
Fax    
Email  gaurielurker@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof Cherishma Dsilva 
Designation  Professor  
Affiliation  Father Muller Medical College  
Address  Father Muller Medical College, Physiotherapy Department, Kankanady, Mangalore Dakshina Kannada Karnataka 575002 India

Dakshina Kannada
KARNATAKA
575002
India 
Phone  9663558311  
Fax    
Email  cheri8585@fathermuller.in  
 
Details of Contact Person
Public Query
 
Name  Gouri Elurker  
Designation  MPT  
Affiliation  Father Muller Medical College  
Address  Father Muller Medical College, Physiotherapy Department, Kankanady, Mangalore Dakshina Kannada Karnataka 575002 India

Dakshina Kannada
KARNATAKA
575002
India 
Phone  7447240180  
Fax    
Email  gaurielurker@gmail.com  
 
Source of Monetary or Material Support  
Father Muller Medical College, Kankanady, Mangalore,Dakshina Kannada,Karnataka 575002 
 
Primary Sponsor  
Name  Father Muller Medical College 
Address  Father Muller Medical College,Kankanady,Dakshina kannada,Mangalore,Karnataka 575002 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
Nil  Nil 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Gouri Elurker  Father Muller Medical College  Department of physiotherapy,Dakshina kannada,Karnataka
Dakshina Kannada
KARNATAKA 
7447240180

gaurielurker@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Father Muller Institutional Ethics Committee(FMIEC)  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Nil  Nil 
 
Inclusion Criteria  
Age From  19.00 Year(s)
Age To  75.00 Year(s)
Gender  Both 
Details  patients diagnosed with breast cancer stage 3-4 receiving chemo-radiation therapy.
all genders.
age: 19-75 years. 
 
ExclusionCriteria 
Details  Cardiovascular conditions such as coronary artery disease, uncontrolled angina, ischemic heart disease.
neurological condition such as stroke, Parkinson disease, Guillain barre syndrome.
Musculoskeletal condition such as dislocation, strain, sprain.
Hb count <8mg/dL.
Inability to comply with study procedure. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
six minute walk test  baseline and 16 weeks post radiation therapy 
 
Secondary Outcome  
Outcome  TimePoints 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(EORTC QLQ)-30  baseline and 16 weeks post radiation therapy 
 
Target Sample Size   Total Sample Size="40"
Sample Size from India="40" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   05/11/2022 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Need for the study:

Breast cancer is most frequently diagnosed and one of the leading cancers amongst women worldwide. Breast cancer arises when there is growth of the malignant or cancer-causing cells in either ducts or lobules of the breast. Lump in the breast, change in the size of breast, fluid discharge from the nipple, dimpling of the skin and red or scaly patch on the breast can be the signs of breast carcinoma. Certain risk factors associated with breast cancer includes obesity, physical inactivity, alcohol, early menarche and late menopause, family history and BRCA1/ BRCA2 gene mutation. According to the site invaded by cancerous cells, breast cancer can be either invasive type which means that it is limited to one part and non-invasive type that is spreading to the other parts. Non-invasive type includes lobular carcinoma (developing in breast lobules) and ductal carcinoma (developing in breast ducts) whereas invasive type includes infiltrating lobular carcinoma, infiltrating ductal carcinoma, medullary carcinoma, mucinous carcinoma and tubular carcinoma.

Early detection and treatment increase the rate of survival of cancer patients, hence every woman should get themselves screened for breast cancer atleast once a year. Different diagnostic methods available for cancer diagnosis include mammography, needle biopsy of breast, ultrasound, PET scan (positron emission tomography), MRI and most importantly self-examination. Early intervention and treatment techniques of chemotherapy, radiation therapy, surgery and hormone therapy can help an individual lower the risks and spreading of the cancer. Chemotherapy is the administration of drugs to destroy the cancer cells and is given before surgery and is continued after surgery too. Surgery is either total mastectomy or radical mastectomy. In total mastectomy whole breast is removed whereas in radical mastectomy only the cancerous region from the breast is removed preserving the other breast tissue. Another method used is radiation therapy that destroy the microscopic tumor cells, this is often followed by surgical management, it can be either external beam radiotherapy or internal radiotherapy. Hormone therapy is used mainly when some cancer cells require estrogen for its growth, hence through hormone therapy estrogen receptors are block to prevent the growth of these cells.

Cancer patients undergoing treatment will pursue various side effects like nausea, vomiting, weight gain, sleep disturbance, fatigue and various heart related problems. These symptoms eventually affect their quality of living making a negative impact on their day-to-day activities. Fatigue has major impact on a person’s physical, social and emotional dimension on quality of life along with other factors such as age, educational level, stage of the cancer and diagnosis of the disease itself.

European Organization for Research and Treatment of Cancer (EORTC) has created several questionnaires to assess the Quality of Life (QOL) of cancer patients which is available in different languages. QLQ-30 is one of the questionnaires used to study about the QOL in breast cancer patients over past week which includes 30 items. Questionnaire contains functional scale, symptom scale and Global health status/QOL scale.

 

6 Minute Walk Test(6MWT) is an assessment tool for measuring functional capacity of an individual. There requires no equipment but only a straight hard pathway of 100ft to perform the test. Indicated to measure exercise capacity in patients or response to any medical intervention. Test to be avoided on individuals having angina or myocardial infarction in recent time of past few months or hypertensive patients (>180/100mmHg). Distance covered by the individual at the end of 6 minutes has to be noted along with the perceived exertion on Borgs scale.

Minimally clinical important difference (MCID) is a clinical measure to assess the changes in one’s treatment outcome which an individual identifies as important. MCID is calculated by distribution-based method and anchor-based method. Data in distribution-based method relies on standard deviation, standard error of the mean change and standard deviation of stable group whereas anchor-based method depends upon the changes reported by the patient.

Chemotherapy induced complications such as decline in cardiopulmonary fitness has major impact on QOL in patients with breast cancer. 6MWT is used as an outcome tool to assess functional capacity and has strong correlation to QOL. As per our knowledge there is no evidence estimating MCID of patients with breast cancer undergoing chemotherapy, hence this justifies the need to conduct the study.

 

RESEARCH QUESTION

Is there any MCID in 6 MWD in breast cancer patients from the baseline (pretreatment) and after 16 weeks?

 

HYPOTHESIS (H1):

There will be MCID in 6MWD in breast cancer patients from baseline (pretreatment) to 16 weeks after beginning with chemotherapy treatment.

 

NULL HYPOTHESIS (H0):

 

There will be no MCID in 6MWD in breast cancer patients from baseline (pretreatment) to 16 weeks after beginning chemotherapy treatment.

 
Close